BALTIMORE--(BUSINESS WIRE)--BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. BioMarker Strategies is developing the patent-pending, SnapPath™ testing system to enable oncologists to determine the most effective drug treatment for their cancer patients. During this funding round, the largest investment came from the Abell Foundation (www.abell.org), a charitable organization dedicated to the enhancement of the quality of life in Baltimore, Maryland, including the promotion of job growth in the region.
